M. D. Ezekowitz
About
In The Last Decade
M. D. Ezekowitz
11 papers receiving 164 citations
Peers
Comparison fields: 5 of 38
- Cardiology and Cardiovascular Medicine 145
- Internal Medicine 97
- Hematology 24
- Epidemiology 17
- Pulmonary and Respiratory Medicine 7
Countries citing papers authored by M. D. Ezekowitz
This map shows the geographic impact of M. D. Ezekowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. D. Ezekowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. D. Ezekowitz more than expected).
Fields of papers citing papers by M. D. Ezekowitz
This network shows the impact of papers produced by M. D. Ezekowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. D. Ezekowitz. The network helps show where M. D. Ezekowitz may publish in the future.
Co-authorship network of co-authors of M. D. Ezekowitz
This figure shows the co-authorship network connecting the top 25 collaborators of M. D. Ezekowitz. A scholar is included among the top collaborators of M. D. Ezekowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. D. Ezekowitz. M. D. Ezekowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation : insights from the RE-LY trial | 1 |
| 3 | Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial | 2 |
| 4 | Bleeding and thromboembolic outcomes in warfarin-and dabigatran-treated patients in the RE-LY trial who required an urgent surgery or procedure | 1 |
| 5 | 53 | |
| 6 | 100 | |
| 7 | 9 | |
| 8 | 3 | |
| 9 | Systemic cardiac embolism | 1 |
| 10 | 1 | |
| 11 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.